多烯紫杉醇联合顺铂治疗非小细胞肺癌的临床疗效分析

Tocetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer

目的评价多烯紫杉醇(TAX)联合顺铂化疗治疗非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法30例晚期NSCLC患者采用多烯紫杉醇75mg/m2、d1,顺铂30mg/m2、d1～3进行治疗。3周为1个周期,均治疗2个周期。结果30例NSCLC中,完全缓解2例、部分缓解14例、稳定7例、进展7例,总有效率53.3%(16/30)。主要毒副作用为骨髓抑制、胃肠道反应、肌肉及关节疼痛。结论TAX联合顺铂治疗NSCLC具有较好的疗效,毒副作用可以耐受。

Objective To evaluate the efficacy and side effects of the combination of tocetaxel and cisplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods Thirty patients were treated with the combination for two courses. Every three weeks, tocetaxel was administrated on day 1 in a dose of 75mg/m^2 and cisplatin in dose of 30mg/m^2 from day 1 to day 3. Results Complete remission was found in two patients, partial remission in fourteen patients, in seven patients there was no change, and in seven patients there was an advance of the disease. The overall remission rate was 53. 3%. The main side effects were suppression of myelopoiesis, gastrointestinal disturbance, alopecia, myalgia and arthralgia. Condusion The combination of tocetaxel and cisplatin is effective and welltolerated in the treatment of NSCLC.